Pneumologie 2023; 77(S 01): S57
DOI: 10.1055/s-0043-1761002
Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*
F Bonella
1
Klinik für Pneumologie, Ruhrlandklinik, Westdeutsches Lungenzentrum, Universitätsklinikum der Universität Duisburg-Essen; Zentrum für Interstitielle und Seltene Lungenkrankheiten, Abteilung Pneumologie; Ruhrlandklinik, Universitätsmedizin Essen
,
T Moua
2
Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, Mn, USA
,
M Okamoto
3
Department of Internal Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Japan
,
S Tomassetti
4
Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy
,
C Valenzuela
5
Hospital Universitario de la Princesa, Universidad Autonoma de Madrid, Madrid, Spain
,
W Wuyts
6
Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
,
C Miede
7
Mainanalytics GmbH, Sulzbach (Taunus), Germany
,
D Lievens
8
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
,
E Bendstrup
9
Centre for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
› Author Affiliations
